Developer docs
API playgroundTry for free, no card

Search company profiles

āshibio

Full company profile

uuid0000gt5

Namestring
āshibio
Legal namestring
ashibio, Inc.
Websiteurl
ashibio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

āshibio is a privately held clinical-stage biotechnology company founded in 2022 and headquartered in Burlingame, California. It develops monoclonal antibody therapies for rare bone and connective-tissue disorders whose principal target indications are described as having no approved treatments. Its pipeline has two clinical-stage candidates: andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-FZD antibody that inhibits Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2).

Andecaliximab inhibits MMP-9, which releases local Activin-A in FOP and BMP ligands in NHHO, pathways that contribute to heterotopic ossification. It has previously been administered to approximately 1,000 patients in cancer and inflammatory-disease trials and is being evaluated in the Phase 2/3 ANDECAL study for FOP and the Phase 1b ANDECA-HO study for patients with spinal cord injury at risk of heterotopic ossification. Vantictumab has prior safety and pharmacokinetic experience in approximately 100 oncology patients and has produced preclinical rescue of the bone phenotype in an ADO2 mouse model. āshibio plans to file an IND for vantictumab in 2026 and initiate ADO2 clinical development.

The company is pre-revenue and has no approved commercial products or publicly disclosed pricing. Its future revenue model is expected to rely on specialty-pharmaceutical commercialization, with specialist prescribing at academic medical centers and specialized treatment centers, dispensing through specialty pharmacies, and reimbursement through public and private insurers. āshibio obtained andecaliximab through an exclusive license from Gilead Sciences and vantictumab through an exclusive license from Mereo BioPharma covering the United States and rest of world, excluding Europe, where Mereo retains commercial rights.

Short descriptiontext

āshibio is a privately held, clinical-stage biotechnology company developing antibody therapies for rare bone and connective-tissue disorders, including FOP, non-hereditary heterotopic ossification, and autosomal dominant osteopetrosis type 2, for patients with limited treatment options.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, rare bone disease therapy, heterotopic ossification treatment, clinical-stage biotechnology, orphan drug development
Industry2 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic product sales (future)
TypeOne Time License
Description

Āshibio is a pre-revenue, clinical-stage biotech company. Its revenue model will ultimately depend on the commercialization of its investigational therapies. As a rare-disease-focused company, therapies could be positioned for premium pricing under orphan drug designations (FDA Orphan Drug Designation for andecaliximab in FOP; EMA Orphan Drug Designation as well), with potential for accelerated approval pathways. The company holds an exclusive license to develop and commercialize vantictumab globally, excluding Europe where Mereo BioPharma retains commercial rights.

ashibio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Āshibio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for rare bone and connective tissue disorders with no approved treatments. Its pipeline includes andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-Fzd antibody that modulates Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2). Both candidates are supported by peer-reviewed foundational research, exclusive inbound licenses, and FDA/EMA Orphan Drug Designations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • MMP9-deficient mice were significantly protected against formation of HO compared to control group (p<0.0001) in a burn-tenotomy model of NHHO
+3 more records
Product overview1 text field

āshibio is a clinical-stage biotechnology company developing a pipeline of novel therapeutics for the treatment of bone and connective tissue disorders. The company has two clinical-stage investigational antibody therapies: andecaliximab (an MMP-9 inhibitor being developed for heterotopic ossification disorders including FOP and NHHO) and vantictumab (a frizzled receptor antibody targeting Wnt signaling for autosomal dominant osteopetrosis type 2). These are distinct therapeutic candidates targeting different rare bone diseases through novel mechanisms.

Product and service2 records
1Andecaliximab
CategoryInvestigational therapeutic monoclonal antibody
Description

Humanized monoclonal antibody that specifically inhibits matrix metalloproteinase-9 (MMP-9), being developed as an investigational therapy for disorders characterized by heterotopic ossification including fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO) following spinal cord injury, traumatic brain injury, hip arthroplasty, burns, and other trauma. Licensed from Gilead Sciences and targeted at specialist physicians at academic medical centers.

2Vantictumab
CategoryInvestigational therapeutic monoclonal antibody
Description

Monoclonal antibody that selectively binds to certain frizzled (Fzd) receptors and inhibits Wnt signaling pathways, being developed as an investigational therapy for autosomal dominant osteopetrosis type 2 (ADO2), also known as Albers-Schönberg disease. Licensed from Mereo BioPharma for global development and commercialization (excluding Europe). Targeted at specialist physicians treating patients with the most common form of osteopetrosis.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2025-08-19
Description

Āshibio entered an exclusive licensing agreement with Mereo BioPharma for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). Āshibio holds an exclusive license to develop and commercialize vantictumab globally, excluding Europe, where Mereo retains commercial rights. Mereo BioPharma also retains certain milestone payments and royalties. The partnership was announced August 19, 2025. Additionally, āshibio's partner Mereo BioPharma plans a Phase 2 trial of vantictumab in autosomal dominant osteopetrosis type 2 for the second half of 2026.

2Dipal Doshi (CEO, Entrada Therapeutics)
Strategic tierCoreTypeOthersAnnounced on2024-09-17
Description

Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), was appointed to āshibio's Board of Directors. Dipal has significant experience setting strategy and driving operational and commercial growth of biopharma companies, having led Entrada's advancement into the clinic, completion of multiple private financings, its successful IPO in 2021, and execution of a transformational business development collaboration.

ashibio.com
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2024-06-20
Description

Āshibio licensed andecaliximab (anti-MMP-9 antibody) from Gilead Sciences. The antibody was originally developed by Arresto Biosciences (where āshibio CSO Victoria Smith was a co-inventor), which was acquired by Gilead. George Wang, Senior Director of Corporate Development at Gilead Sciences, serves as a Board Observer at āshibio.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Dr. Frederick Kaplan's laboratory at the University of Pennsylvania led to the discovery that MMP-9 could serve as a novel therapeutic target for FOP. The research, published in Journal of Bone and Mineral Research in February 2024, described a unique 35-year-old patient with the classic FOP mutation who was protected from heterotopic ossification due to an additional MMP-9 mutation. Dr. Kaplan is Isaac and Rose Nassau Professor of Orthopaedic Molecular Medicine at UPenn.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Dr. Michael Econs' laboratory at Indiana University School of Medicine demonstrated that vantictumab rescues the bone phenotype in a mouse model of ADO2. Dr. Econs is Distinguished Professor and Director of the Division of Endocrinology and Metabolism. Imranul Alam, PhD, Associate Research Professor of Medicine at IU, presented the vantictumab preclinical data at ASBMR 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UCSF served as an enrollment site for the ANDECAL Phase 2/3 trial of andecaliximab in FOP. Dr. Edward Hsiao, Professor in the Division of Endocrinology and Metabolism and Director of the Metabolic Bone Clinic at UCSF, enrolled the first participant in the trial. Dr. Hsiao is a co-author of the foundational MMP-9 research published in JBMR.

7Craig Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Craig Hospital in Englewood, Colorado served as a clinical trial site for the ANDECA-HO Phase 1b trial of andecaliximab in spinal cord injury patients at risk of HO. Dr. Andrew Park, Physician Scientist at Craig Hospital, is the Principal Investigator and dosed the first patient in the SCI study.

ashibio.com
8IFOPA (International FOP Association)
Strategic tierCoreTypeOthers
Description

IFOPA is a patient advocacy organization for individuals with FOP and their families. Āshibio participates in IFOPA's Drug Development Forum and collaborates with IFOPA to raise disease awareness and support clinical trial enrollment. The company's FOP Drug Development Forum presentation was scheduled for June 27-28, 2024 in Stockholm, Sweden.

ashibio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Inozyme Pharma is a clinical-stage rare disease biotech developing therapies for disorders of bone mineralization and soft tissue calcification. Directly comparable to āshibio because both target rare bone diseases with no approved therapies; notably, āshibio's CMO Deborah Wenkert was previously CMO at Inozyme Pharma.

TypeDirect peer
Description

Mereo BioPharma is a clinical-stage rare disease biotech focused on rare bone diseases and other rare conditions. Directly comparable as āshibio's licensing partner for vantictumab in ADO2, with Mereo also developing rare bone disease therapies and retaining EU commercial rights for vantictumab.

TypeDirect peer
Description

Ultragenyx is a commercial-stage rare disease biotech with multiple approved rare disease therapies including treatments for rare bone and metabolic disorders (e.g., Crysvita for X-linked hypophosphatemia). Highly comparable as a rare bone disease-focused biotech with both approved and clinical-stage assets.

TypeBroad incumbent
Description

Alexion, now part of AstraZeneca, is a global leader in rare disease therapeutics with multiple approved products for ultra-rare conditions including rare metabolic and bone disorders. Broad incumbent with overlapping rare disease commercialization capabilities and complementary pipeline.

TypeBroad incumbent
Description

BioMarin is a global rare disease biotech with multiple approved enzyme replacement and biologic therapies for ultra-rare conditions, including rare metabolic bone disorders. Comparable as a specialized rare disease commercial-stage company with a development pipeline in adjacent indications.

TypeBroad incumbent
Description

Regeneron is a leading antibody therapeutics platform company with multiple approved monoclonal antibodies and a pipeline spanning rare diseases, bone/eye disorders, and oncology. Comparable for its antibody development capabilities and clinical-stage rare disease pipeline, though it operates across many indications beyond bone.

TypeDirect peer
Description

BridgeBio is a clinical-stage biotech developing therapies for genetic diseases including rare bone and metabolic disorders (e.g., Accrufer for iron deficiency). Comparable as a rare disease-focused biotech pursuing novel mechanisms in genetically defined patient populations.

TypeEmerging player
Description

Disc Medicine is a clinical-stage rare disease biotech developing therapeutics for hematologic disorders including rare bone marrow conditions. Comparable as an emerging rare disease biotech using novel mechanisms in small, well-defined patient populations, though it focuses on hematology rather than bone directly.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

āshibio

Rare Disease Biopharmaceuticalsashibio.com

āshibio is a privately held, clinical-stage biotechnology company developing antibody therapies for rare bone and connective-tissue disorders, including FOP, non-hereditary heterotopic ossification, and autosomal dominant osteopetrosis type 2, for patients with limited treatment options.

What āshibio does

āshibio is a privately held clinical-stage biotechnology company founded in 2022 and headquartered in Burlingame, California. It develops monoclonal antibody therapies for rare bone and connective-tissue disorders whose principal target indications are described as having no approved treatments. Its pipeline has two clinical-stage candidates: andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-FZD antibody that inhibits Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2).

Andecaliximab inhibits MMP-9, which releases local Activin-A in FOP and BMP ligands in NHHO, pathways that contribute to heterotopic ossification. It has previously been administered to approximately 1,000 patients in cancer and inflammatory-disease trials and is being evaluated in the Phase 2/3 ANDECAL study for FOP and the Phase 1b ANDECA-HO study for patients with spinal cord injury at risk of heterotopic ossification. Vantictumab has prior safety and pharmacokinetic experience in approximately 100 oncology patients and has produced preclinical rescue of the bone phenotype in an ADO2 mouse model. āshibio plans to file an IND for vantictumab in 2026 and initiate ADO2 clinical development.

The company is pre-revenue and has no approved commercial products or publicly disclosed pricing. Its future revenue model is expected to rely on specialty-pharmaceutical commercialization, with specialist prescribing at academic medical centers and specialized treatment centers, dispensing through specialty pharmacies, and reimbursement through public and private insurers. āshibio obtained andecaliximab through an exclusive license from Gilead Sciences and vantictumab through an exclusive license from Mereo BioPharma covering the United States and rest of world, excluding Europe, where Mereo retains commercial rights.

āshibio firmographics

Firmographics
Name
āshibio
Legal name
ashibio, Inc.
Website
https://ashibio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
āshibio is a privately held, clinical-stage biotechnology company developing antibody therapies for rare bone and connective-tissue disorders, including FOP, non-hereditary heterotopic ossification, and autosomal dominant osteopetrosis type 2, for patients with limited treatment options.
Ownership category
akta.pro rank

āshibio industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Monoclonal antibody therapeutics
  • Rare bone disease therapy
  • Heterotopic ossification treatment
  • Clinical-stage biotechnology
  • Orphan drug development

Where āshibio is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Offices1 record

Markets served

āshibio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Therapeutic product sales (future): Āshibio is a pre-revenue, clinical-stage biotech company. Its revenue model will ultimately depend on the commercialization of its investigational therapies. As a rare-disease-focused company, therapies could be positioned for premium pricing under orphan drug designations (FDA Orphan Drug Designation for andecaliximab in FOP; EMA Orphan Drug Designation as well), with potential for accelerated approval pathways. The company holds an exclusive license to develop and commercialize vantictumab globally, excluding Europe where Mereo BioPharma retains commercial rights.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

āshibio product offering

Product offering

Core offering

Āshibio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for rare bone and connective tissue disorders with no approved treatments. Its pipeline includes andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-Fzd antibody that modulates Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2). Both candidates are supported by peer-reviewed foundational research, exclusive inbound licenses, and FDA/EMA Orphan Drug Designations.

Product overview

āshibio is a clinical-stage biotechnology company developing a pipeline of novel therapeutics for the treatment of bone and connective tissue disorders. The company has two clinical-stage investigational antibody therapies: andecaliximab (an MMP-9 inhibitor being developed for heterotopic ossification disorders including FOP and NHHO) and vantictumab (a frizzled receptor antibody targeting Wnt signaling for autosomal dominant osteopetrosis type 2). These are distinct therapeutic candidates targeting different rare bone diseases through novel mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Andecaliximab Humanized monoclonal antibody that specifically inhibits matrix metalloproteinase-9 (MMP-9), being developed as an investigational therapy for disorders characterized by heterotopic ossification including fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO) following spinal cord injury, traumatic brain injury, hip arthroplasty, burns, and other trauma. Licensed from Gilead Sciences and targeted at specialist physicians at academic medical centers.
  • Vantictumab Monoclonal antibody that selectively binds to certain frizzled (Fzd) receptors and inhibits Wnt signaling pathways, being developed as an investigational therapy for autosomal dominant osteopetrosis type 2 (ADO2), also known as Albers-Schönberg disease. Licensed from Mereo BioPharma for global development and commercialization (excluding Europe). Targeted at specialist physicians treating patients with the most common form of osteopetrosis.

Quantifiable outcome

  • MMP9-deficient mice were significantly protected against formation of HO compared to control group (p<0.0001) in a burn-tenotomy model of NHHO
  • +3 more outcomes

Companies that use āshibio

Customer profile

Segments3 records

Ideal customer profiles1 record

āshibio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

āshibio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship and core.

  • Mereo BioPharmaflagshipTechnology or Integration · 19 August 2025Āshibio entered an exclusive licensing agreement with Mereo BioPharma for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). Āshibio holds an exclusive license to develop and commercialize vantictumab globally, excluding Europe, where Mereo retains commercial rights. Mereo BioPharma also retains certain milestone payments and royalties. The partnership was announced August 19, 2025. Additionally, āshibio's partner Mereo BioPharma plans a Phase 2 trial of vantictumab in autosomal dominant osteopetrosis type 2 for the second half of 2026.
  • Dipal Doshi (CEO, Entrada Therapeutics)coreOthers · 17 September 2024Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), was appointed to āshibio's Board of Directors. Dipal has significant experience setting strategy and driving operational and commercial growth of biopharma companies, having led Entrada's advancement into the clinic, completion of multiple private financings, its successful IPO in 2021, and execution of a transformational business development collaboration.
  • Gilead Sciences, Inc.flagshipTechnology or Integration · 20 June 2024Āshibio licensed andecaliximab (anti-MMP-9 antibody) from Gilead Sciences. The antibody was originally developed by Arresto Biosciences (where āshibio CSO Victoria Smith was a co-inventor), which was acquired by Gilead. George Wang, Senior Director of Corporate Development at Gilead Sciences, serves as a Board Observer at āshibio.
  • University of Pennsylvania (Dr. Frederick Kaplan lab)coreStrategic or Co-development PartnerResearch collaboration with Dr. Frederick Kaplan's laboratory at the University of Pennsylvania led to the discovery that MMP-9 could serve as a novel therapeutic target for FOP. The research, published in Journal of Bone and Mineral Research in February 2024, described a unique 35-year-old patient with the classic FOP mutation who was protected from heterotopic ossification due to an additional MMP-9 mutation. Dr. Kaplan is Isaac and Rose Nassau Professor of Orthopaedic Molecular Medicine at UPenn.
  • Indiana University School of Medicine (Dr. Michael Econs lab)coreStrategic or Co-development PartnerResearch collaboration with Dr. Michael Econs' laboratory at Indiana University School of Medicine demonstrated that vantictumab rescues the bone phenotype in a mouse model of ADO2. Dr. Econs is Distinguished Professor and Director of the Division of Endocrinology and Metabolism. Imranul Alam, PhD, Associate Research Professor of Medicine at IU, presented the vantictumab preclinical data at ASBMR 2025.
  • University of California, San Francisco (UCSF)coreStrategic or Co-development PartnerUCSF served as an enrollment site for the ANDECAL Phase 2/3 trial of andecaliximab in FOP. Dr. Edward Hsiao, Professor in the Division of Endocrinology and Metabolism and Director of the Metabolic Bone Clinic at UCSF, enrolled the first participant in the trial. Dr. Hsiao is a co-author of the foundational MMP-9 research published in JBMR.
  • Craig HospitalcoreStrategic or Co-development PartnerCraig Hospital in Englewood, Colorado served as a clinical trial site for the ANDECA-HO Phase 1b trial of andecaliximab in spinal cord injury patients at risk of HO. Dr. Andrew Park, Physician Scientist at Craig Hospital, is the Principal Investigator and dosed the first patient in the SCI study.
  • IFOPA (International FOP Association)coreOthersIFOPA is a patient advocacy organization for individuals with FOP and their families. Āshibio participates in IFOPA's Drug Development Forum and collaborates with IFOPA to raise disease awareness and support clinical trial enrollment. The company's FOP Drug Development Forum presentation was scheduled for June 27-28, 2024 in Stockholm, Sweden.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

āshibio competitors and assessment

Company assessment

Direct peers

  • Inozyme Pharma: Inozyme Pharma is a clinical-stage rare disease biotech developing therapies for disorders of bone mineralization and soft tissue calcification. Directly comparable to āshibio because both target rare bone diseases with no approved therapies; notably, āshibio's CMO Deborah Wenkert was previously CMO at Inozyme Pharma.
  • Mereo BioPharma: Mereo BioPharma is a clinical-stage rare disease biotech focused on rare bone diseases and other rare conditions. Directly comparable as āshibio's licensing partner for vantictumab in ADO2, with Mereo also developing rare bone disease therapies and retaining EU commercial rights for vantictumab.
  • Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease biotech with multiple approved rare disease therapies including treatments for rare bone and metabolic disorders (e.g., Crysvita for X-linked hypophosphatemia). Highly comparable as a rare bone disease-focused biotech with both approved and clinical-stage assets.
  • BridgeBio Pharma: BridgeBio is a clinical-stage biotech developing therapies for genetic diseases including rare bone and metabolic disorders (e.g., Accrufer for iron deficiency). Comparable as a rare disease-focused biotech pursuing novel mechanisms in genetically defined patient populations.

Broad incumbents

  • Alexion / AstraZeneca Rare Disease: Alexion, now part of AstraZeneca, is a global leader in rare disease therapeutics with multiple approved products for ultra-rare conditions including rare metabolic and bone disorders. Broad incumbent with overlapping rare disease commercialization capabilities and complementary pipeline.
  • BioMarin Pharmaceutical: BioMarin is a global rare disease biotech with multiple approved enzyme replacement and biologic therapies for ultra-rare conditions, including rare metabolic bone disorders. Comparable as a specialized rare disease commercial-stage company with a development pipeline in adjacent indications.
  • Regeneron Pharmaceuticals: Regeneron is a leading antibody therapeutics platform company with multiple approved monoclonal antibodies and a pipeline spanning rare diseases, bone/eye disorders, and oncology. Comparable for its antibody development capabilities and clinical-stage rare disease pipeline, though it operates across many indications beyond bone.

Emerging players

  • Disc Medicine: Disc Medicine is a clinical-stage rare disease biotech developing therapeutics for hematologic disorders including rare bone marrow conditions. Comparable as an emerging rare disease biotech using novel mechanisms in small, well-defined patient populations, though it focuses on hematology rather than bone directly.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

āshibio social profiles

Digital presence

āshibio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

āshibio leadership team

Management profile

Number of profiles

Profiles11 records

āshibio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

āshibio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about āshibio

What does āshibio do?

Āshibio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for rare bone and connective tissue disorders with no approved treatments. Its pipeline includes andecaliximab, a humanized anti-MMP-9 antibody for fibrodysplasia ossificans progressiva (FOP) and non-hereditary heterotopic ossification (NHHO), and vantictumab, an anti-Fzd antibody that modulates Wnt signaling for autosomal dominant osteopetrosis type 2 (ADO2). Both candidates are supported by peer-reviewed foundational research, exclusive inbound licenses, and FDA/EMA Orphan Drug Designations.

Is āshibio a public or private company?

āshibio is a private company. It is classified as venture growth investor backed and is currently operating.

When was āshibio founded?

āshibio was founded in 2022. It employs 1 to 10 people.

Where is āshibio based?

āshibio is headquartered in Brisbane, United States, in the North America region.

How does āshibio make money?

One revenue line is on record: therapeutic product sales (future).

Who are āshibio's main competitors?

Direct peers on record are Inozyme Pharma, Mereo BioPharma, Ultragenyx Pharmaceutical and BridgeBio Pharma. Broad incumbents are Alexion / AstraZeneca Rare Disease, BioMarin Pharmaceutical and Regeneron Pharmaceuticals. Disc Medicine is listed as an emerging player.

Does āshibio have an API?

No public API is recorded for āshibio.

What industry is āshibio in?

āshibio's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire Blogāshibio Presents Preliminary Efficacy Data for Andecaliximab Demonstrating an 86.2% Reduction in New Flare-Up Rate in Patients with FOPāshibio presented preliminary efficacy data from Part 1 of its Phase 2/3 ANDECAL study at ASBMR 2026, showing an 86.2% reduction in new flare-up rate with andecaliximab at 300mg/week. Of 12 enrolled participants, 11 carried the R206H variant, and 92% had new flare-ups within 2.5 months prior to baseline.Business Wire Blogāshibio Presents Biomarker Data Supporting Vantictumab Development for ADO2 and a Prevalence Estimate of CLCN7-Related ADO2 of 1–4 per 20,000 Individualsāshibio presented biomarker data at ASBMR 2026 showing vantictumab activates osteoclasts at low doses without inhibiting osteoblasts, supporting its development for ADO2. Genetic analysis estimated CLCN7-related ADO2 prevalence at 1–4 per 20,000 individuals, consistent with prior estimates. The company plans to advance vantictumab into clinical trials in the first half of 2028.FinancialContent Business Pageāshibio Presents Biomarker Data Supporting Vantictumab Development for ADO2 and a Prevalence Estimate of CLCN7-Related ADO2 of 1–4 per 20,000 Individualsāshibio presented biomarker data at ASBMR 2026 showing low-dose vantictumab activates osteoclasts without inhibiting osteoblasts, supporting its development for ADO2. A genetic database analysis estimated CLCN7-related ADO2 prevalence at 1–4 per 20,000 individuals. The company plans to advance vantictumab into ADO2 clinical trials in the first half of 2028.BioSpaceāshibio to Present Three Abstracts at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meetingāshibio will present three abstracts at the ASBMR 2026 annual meeting in Boston, including the first efficacy data from the Phase 2/3 ANDECAL study of andecaliximab for fibrodysplasia ossificans progressiva. The company also plans to advance vantictumab into clinical trials for autosomal dominant osteopetrosis type 2.openPR.comFibrodysplasia Ossificans Progressiva Market Outlook 2032: Rising Prevalence and Innovative Pipeline Therapies Drive Growth, analyses DelveInsightDelveInsight published a market research report projecting substantial growth in the Fibrodysplasia Ossificans Progressiva (FOP) market through 2032, driven by increasing disease awareness and a growing pipeline of therapies. In September 2025, Regeneron reported positive Phase III results for its drug garetosmab and plans to seek FDA approval by year-end, while ashibio initiated dosing in its Phase 2/3 clinical trial for andecaliximab in January 2025. The report identifies the United States as the leading market among the seven major markets and lists key therapies including Palovarotene (Ipsen), Garetosmab (Regeneron), and BCX9250 (BioCryst).Yahooāshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directorsāshibio appointed Dipal Doshi, CEO of Entrada Therapeutics, to its board. The company exited stealth mode in June 2024 with $40 million in seed and Series A financing. It plans to initiate a Phase 2/3 trial of its lead asset in the second half of 2024.Business Wire Blogāshibio Raises $40M in Seed and Series A Financing to Advance Therapies for Bone and Connective Tissue Disordersāshibio exited stealth mode with $40 million in seed and Series A financing, led by MPM BioImpact. The company plans a Phase 2/3 trial of andecaliximab for fibrodysplasia ossificans progressiva in the second half of 2024. The FDA designated the drug an orphan drug in March 2024.